| Brimonidine | Galderma | ||
| EQ 0.33% BASE; Gel, Topical |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
Less Than 5
|
None | ||
|
Less Than 5
|
Less Than 5
|
||
| Indicated for the topical treatment of persistent (nontransient) erythema of rosacea in adults 18 years of age or older. | |||
|
Yes
| |||
| Mirvaso | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| *********** *** ************ *** ******* ** *** | *********, ************, *** ******* *** ******** ** ********** ******* | *********** *** *********** | *** ************ *** ******* ** *** | *********, ************, *** ******* *** ************ ************** | ******* *** ************ *** ******** ** ********** ******** | *********, ************, *** ******* *** ******** ** ********** ************ **** ********* | ******* *** ************ *** **** *** ********* ********* ** ******** | ******* *** ************ *** **** *** ********* ********* ** ******** | *********, ************, *** ******* *** ******** ** ********** ************ **** ********* | ******* *** ************ *** **** *** ********* ********* ** ******** | ******* *** ************ *** **** *** ********* ********* ** ******** |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ******* | *** \ ** | *** **, **** | ******* | **** | ****** *** **** |
| ******* | ** \ ** | *** **, **** | ******* | ******** | ******** *** **, **** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|